Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer

It is a phase III trial to explore the efficacy and safety of utidelone versus docetaxel in HER2-negative locally advanced or metastatic breast cancer.

Trial Details

NCT ID
NCT05430399
Phase
PHASE3
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • utidelone
  • docetaxel
Locations (sample)
  • Guangzhou, Gangdong, China|23.11667,113.25
  • Hunan, Hunan, China

Key Eligibility Criteria

  • Signed the informed consent form;
  • Women aged ≥ 18 years;
  • Patients with locally advanced or metastatic, histologically or cytologically documented breast cancer;
  • The primary tumor and metastases (if re-biopsy was performed) were both HER2-negative;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →